Intratumoral heterogeneity may be responsible for chemotherapy resistance in patients with small cell lung cancer
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within the tumor, leading to the evolution of multiple resistance mechanisms.
The research team, led by Lauren Averett...
Surgeon General’s e-cigarette advisory brings necessary attention to ‘epidemic’ in youth
The University of Texas MD Anderson Cancer Center supports the United States Surgeon General’s actions to inform youth, parents, teachers...
MD Anderson study shows key enzyme linked to therapy resistance in deadly lung cancer
Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and...
Rex Tillerson honored at A Conversation With a Living Legend
In his first interview since leaving public office in March, former U.S. Secretary of State Rex Tillerson spoke to CBS News' Bob Schieffer about the state of domestic and world affairs at a dinner Dec. 6 benefiting The University of Texas MD Anderson Cancer Center. More than 850 MD Anderson supporters attended the 10th annual A Conversation With a Living Legend® in Houston, which raised more than $1.78 million for cancer research...
More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial
A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent...
In Memory of President George H.W. Bush
MD Anderson extends deepest sympathy to the family of former President George H.W. Bush. The institution mourns the loss of an extraordinary...
MD Anderson, Houston Dynamo team up for one goal: end cancer
The University of Texas MD Anderson Cancer Center and the Houston Dynamo today announced plans to work together toward one goal: end cancer...
Peers choose MD Anderson’s Gershenwald, Hwu as new AAAS Fellows
Two leaders in the field of melanoma treatment – a surgeon and an oncologist – from The University of Texas MD Anderson Cancer Center have...
Stand Up to Cancer funds innovative approach to pancreatic cancer
Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new...
FDA restrictions on e-cigarettes an important step to protect the health of youth
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit...
Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp...
Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called...
First UT System clinical collaboration launches between MD Anderson, UTMB Health
The University of Texas MD Anderson Cancer Center today formally opened a four-story facility in League City that houses new and expanded...
Fecal transplant effective against immunotherapy-induced colitis
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused...
Combination chemotherapy and immunotherapy effective in Phase II leukemia study
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated...
Minimally invasive surgery associated with worse survival for women with cervical cancer compared to open hysterectomy
When comparing standard-of-care surgical options for women with early-stage cervical cancer, two studies led by researchers at The University...
MD Anderson slates third annual Boot Walk to End Cancer®
Thanks to a grassroots campaign at Houston-area Walmart stores and generous support from individuals, teams and other corporate sponsors,...
Suppression of DKK3 protein thwarts pancreatic tumor progression and prolongs survival
Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy....
Frances MacDonald receives Brown Foundation Award for Excellence in Oncology Nursing
Frances MacDonald, a clinical nurse in the GI-Colorectal Center at The University of Texas MD Anderson Cancer Center, is the recipient of...
RNA thought to spread cancer shows ability to suppress breast cancer metastasis
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma...
Study shows surgery, radiation extend survival of patients with limited metastatic lung cancer
Radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage 4 disease...
MD Anderson fundraiser to honor James A. Baker, III
A Conversation With a Living Legend®, an annual luncheon benefiting The University of Texas MD Anderson Cancer Center, will pay tribute to...
Cancer patients with rare deadly brain infection treated successfully with off-the-shelf adoptive T-cell therapy in clinical trial
An emerging treatment known as adoptive T-cell therapy has proven effective in a Phase II clinical trial for treating progressive multifocal...
Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage 3 melanoma
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma...
MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicines in hematological malignancies
The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement...
Cattlemen for Cancer Research slates annual auction benefiting Keeling Center in Bastrop
Cattlemen for Cancer Research (CCR) will hold its 20th annual auction in Bastrop, Texas, Saturday, Oct. 20, at the Hills Prairie Livestock...
Press Event: MD Anderson immunologist Jim Allison awarded Nobel Prize
Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform at The University of Texas...
MD Anderson immunologist Jim Allison awarded Nobel Prize
Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform at The University of Texas MD Anderson Cancer...
Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers
A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related...
A Conversation With a Living Legend in Dallas to honor major champion Jordan Spieth
A Conversation With a Living Legend® in Dallas will honor PGA TOUR professional Jordan Spieth, Nov. 5 at the Hilton Anatole. CBS Sports'...
Poziotinib maintains high response rate against harmful lung cancer mutation
A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide unprecedented response rates among...
MD Anderson hosts Biden Cancer Community Summit
The University of Texas MD Anderson Cancer Center today joined with more than 450 communities and institutions across the country in hosting...
Largest-Ever Study Shows Silicone Breast Implants Associated with Rare Diseases
In the largest study of long-term safety outcomes for patients with breast implants, researchers at The University of Texas MD Anderson Cancer...
Rogers Award honors Padmanee Sharma, M.D., Ph.D., for excellence in research
Padmanee Sharma, M.D., Ph.D., is the 2018 recipient of the Julie and Ben Rogers Award for Excellence in Research at The University of Texas...
MD Anderson immunotherapy expert Sharma wins Coley Award
Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson...
Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers
Researchers at The University of Texas MD Anderson Cancer Center have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor...
Study finds no difference in disease-free, overall survival for HER2+ breast cancer patients receiving treatment concurrently or sequentially
New research in women with HER2+ breast cancer found no difference in disease-free survival (DFS) and overall survival (OS) when receiving...
Poziotinib sustains high response rates against intractable lung cancer mutation
A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide high response rates among stage 4...
Board of Visitors leadership welcomes new members
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed advisory board of volunteers who advance...
$50 million awarded by CPRIT to MD Anderson and its projects
The University of Texas MD Anderson Cancer Center today was awarded $30 million to support research, core facilities, recruitment and prevention...
Combination immunotherapy shrinks melanoma brain metastases
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the...
PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended...
MD Anderson ranked No. 1 for cancer care in national survey
The University of Texas MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best...
MD Anderson and Accelerator Life Science Partners launch Magnolia Neurosciences to speed development of neuroprotective therapies
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management...
MD Anderson and Jazz Pharmaceuticals collaborate to evaluate potential treatment options for hematologic malignancies
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a...
Comprehensive CAR T-cell therapy pediatric guidelines developed by MD Anderson in collaboration with the Pediatric Acute Lung Injury and Sepsis Investigators network
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children...
Microscopic imaging pierces the “black box” of cancer bone metastasis
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer...
Study shows biomarker panel boosts lung cancer risk assessment for smokers
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing...
Mendelsohn shares Tang Prize for leadership in developing targeted therapy
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center...
Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival...
Researchers find combination can enhance ipilimumab immunotherapy
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors...
MD Anderson, Houston Methodist scientists detect new ovarian cancer target
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug,...
Aspen Making Cancer History® Seminar marks 20th anniversary
The University of Texas MD Anderson Cancer Center will host its 20th annual Making Cancer History® seminar in Aspen, 10 a.m.-12 p.m. Monday...
PARP inhibitor improves overall response rates in small cell lung cancer patients
In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center adding the PARP inhibitor veliparib...
MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and TRACTION...
MD Anderson and nation’s top cancer centers endorse goal of eliminating HPV-related cancers
Recognizing that vaccination rates for the human papillomavirus (HPV) remain low across the U.S., particularly in Texas, The University of...
MD Anderson announces 2018 Andrew Sabin Family Fellows
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family Fellows. As...
Checkpoint inhibitor shrinks advanced squamous cell skin cancer
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of...
First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson...
Erdafitinib shows promise in urothelial cancer patients with specific mutations
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR...
Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable...
Long-term IMPACT data find improved survival when targeted therapies matched to tumor-specific gene mutations
Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival...
MD Anderson Informs Patients of Accidental Disclosure of Email Addresses
The University of Texas MD Anderson Cancer Center today sent letters to individuals whose email addresses were accidentally exposed in a communication...
MD Anderson and Amgen to accelerate early-stage treatments for several cancer types
The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating...
ASCO honors MD Anderson faculty with awards
The American Society of Clinical Oncology (ASCO) will present awards to leaders of cancer care during its annual meeting June 1-5 in Chicago...
MD Anderson and Ipsen announce joint bench-to-bedside cancer drug development partnership
The University of Texas MD Anderson and Ipsen, a global biopharmaceutical group, today announced a global licensing and joint development...
Nursing Leaders from MD Anderson Cancer Center, Seattle Cancer Care Alliance Share Insights on Succession Planning
While some regions of the nation will experience greater nursing shortages than others in the coming years, hospitals and healthcare systems...
Surveillance intensity not associated with earlier detection of recurrence or improved survival in colorectal cancer patients
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity...
Self-reporting with sensor and mobile technology may reduce symptom burden for head and neck cancer patients undergoing radiation treatment
Abstract: 6063
A study led by researchers at The University of Texas MD Anderson Cancer Center found that the use of at-home sensor...
New approach to cancer research aims to accelerate studies and reduce cost
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical...
Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to...
MD Anderson, Spectrum Pharmaceuticals complete poziotinib licensing deal
The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by...
RNA editing study shows potential for more effective precision cancer treatment
If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD...
TMC3 Founding Institutions Chart Unprecedented Course for Life Sciences with New Research Campus
Founding TMC3 institutions – Texas Medical Center (TMC), Baylor College of Medicine, Texas A&M University Health Science Center, The University...
Size, structure help poziotinib pose threat to deadly exon 20 lung cancer
A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable...
Study may explain why some triple-negative breast cancers are resistant to chemotherapy
Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary...
MD Anderson Hosts Free Skin Screenings in Bay Area, Texas Medical Center
The University of Texas MD Anderson Cancer Center will host free skin cancer screenings from 10 a.m. – 1 p.m. on Saturday, May 5 at two of...
MD Anderson researcher elected to American Academy of Arts and Sciences
Richard D. Wood, Ph.D., professor at The University of Texas MD Anderson Cancer Center, has been elected as a member of the American Academy...
Combination therapy strengthens T cells in melanoma pre-clinical study
A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the...
Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies
Just like people, some T cells have excellent memories. These subtypes known as memory T cells may explain why some immunotherapies are more...
Prom Comes to Teen Cancer Patients, in the Hospital
Special Note: All prom events are open to media, including the dress and tux selection, and hair and makeup appointments.
The...
Precancerous colon polyps in patients with Lynch syndrome exhibit immune activation
Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation...
First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers
A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug...
Polo on the Prairie slates country music star Ryan Bingham
Country music fans and polo enthusiasts alike are expected at the 32nd annual Polo on the Prairie, an annual polo match and fundraising event...
Findings from breast and gynecological cancer study may have potential for future clinical applications
Researchers from The University of Texas MD Anderson Cancer Center have found a startling amount of new information about molecular features...
Study of gene enhancers sheds light on how some cancers form and spread
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian...
Making Cancer History® Seminar makes third trip to Midland
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Midland, 11:30 a.m. to 1:30 p.m.,...
MD Anderson and Berkeley Lights launch Optera Therapeutics to accelerate development of cell therapies for cancer
The University of Texas MD Anderson Cancer Center and Berkeley Lights, Inc. today announced the launch of Optera Therapeutics Corp, a biopharmaceutical...
Deeper look at biopsy exposes mutation ready to ambush drug combination
A powerful resistance mutation that appeared to emerge in melanoma after a patient received a targeted therapy combination, instead was lurking...
Future MD Anderson Location in The Woodlands® Tops Out
The University of Texas MD Anderson Cancer Center today celebrated a milestone in the construction of its three-story clinic in The Woodlands...
MD Anderson and RaySearch announce strategic alliance to advance radiation therapy of cancer
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing...
MD Anderson receives $22 million in CPRIT funding for research, prevention and recruitment
The University of Texas MD Anderson Cancer Center was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas...
Kinase inhibitor larotrectinib shows durable anti-tumor abilities in patients of all ages with 17 unique cancer diagnoses
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages...
Obesity associated with longer survival for men with metastatic melanoma
Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal...
Smart bomb virus shows promise as brain tumor immunotherapy
A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma...
Findings suggests potential new area of focus for checkpoint blockade immunotherapy
Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone cancer that accounts for one-fourth of all breast cancers, could...
MD Anderson supports World Cancer Day through commitment to end cancer
The University of Texas MD Anderson Cancer Center and its 20,000 faculty and staff devoted exclusively to patient care, research, education...
MD Anderson study evaluates need for biopsies during follow-up care in women with early breast cancer
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas...
Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared...
National Academy of Sciences awards Kovalenko medal to immunotherapy pioneer Allison
Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive...
MD Anderson and UT Health San Antonio applaud San Antonio City Council for increasing tobacco sale age to 21
The University of Texas MD Anderson Cancer Center and UT Health San Antonio applaud the actions of the San Antonio City Council today in voting...
MD Anderson experts to share latest in cancer treatment, research
Leaders of The University of Texas MD Anderson Cancer Center will head to Palm Beach Jan. 22 to present innovations in cancer research, treatment...
New cancer model shows genomic link between early-stage and invasive breast cancer types
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to...
Small-cell lung cancer patients face barriers to receiving standard-of-care treatment
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management...